Meta Pixel

News and Announcements

Atomo Diagnostics – CEO Interview

  • Published October 27, 2015 6:09PM UTC
  • Publisher Wholesale Investor
  • Categories Executive Interviews

Atomo Diagnostics is a multi-award winning and rapidly growing medical device company that has developed and commercialised AtomoRapid™, the world’s first integrated device for blood based immunoassay rapid diagnostic testing (RDTs) in point of care settings.

Atomo launched its first test on the platform, AtomoRapid HIV, in 2014. Since launch, AtomoRapid tests have quickly established themselves as a “best in class” solution for professional use diagnostic screening.

With tests now commercialised for HIV and malaria and a rapid Ebola test ready for launch later this year, Atomo is disrupting global RDT markets where convenience, usability and safety have for many years been largely overlooked.

Please listen to John Kelly, CEO of Atomo Diagnostics below.

Capital Insights
The Great Life Science Reset: Why the “Sick Care” Model is Failing

The data reveals a significant transition: the end of the traditional sick care model and the rise of a proactive healthcare ecosystem. Learn how smart money is utilising AI to cut drug discovery times in half, transform diagnostics to detect complex diseases in days, and create efficiencies to scale the healthcare system without a proportional increase in costs.

Capital Insights
Australia’s A$4 Trillion Generational Pivot

Australia’s wealth management landscape is undergoing a dramatic transformation. For decades, family offices operated quietly during the “Great Moderation”, an era characterised by low volatility, cheap capital, and global economic synchronisation. Today, that stability has given way to fiscal uncertainty, geopolitical tensions, and intensifying regulatory scrutiny. Yet amid this global turbulence, Australia has emerged as […]

Join over 45,000+ sophisticated investors

Join Now